Page 2213 - Williams Hematology ( PDFDrive )

2188 Part XII: Hemostasis and Thrombosis Chapter 127: Antibody-mediated Coagulation Factor Deficiencies 2189

37. Healey JF, Barrow RT, Tamim HM, et al: Residues Glu2181-Val2243 contain a major 66. Green D, Rademaker AW, Briet E: A prospective, randomized trial of prednisone and
determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb
92(10):3701–3709, 1998. Haemost 70(5):753–757, 1993.
38. Lollar P, Parker ET, Curtis JE, et al: Inhibition of human factor VIIIa by anti-A2 subunit 67. Collins P, Baudo F, Knoebl P, et al: Immunosuppression for acquired hemophilia A:
antibodies. J Clin Invest 93(6):2497–2504, 1994. Results from the European Acquired Haemophilia Registry (EACH2). Blood 120(1):
39. Healey JF, Lubin IM, Nakai H, et al: Residues 484–508 contain a major determi- 47–55, 2012.
nant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 68. Schoenecker JG, Johnson RK, Lesher AP, et al: Exposure of mice to topical bovine
270(24):14505–14509, 1995. thrombin induces systemic autoimmunity. Am J Pathol 159(5):1957–1969, 2001.
40. Arai M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibition by human 69. Ortel TL, Charles LA, Keller FG, et al: Topical thrombin and acquired coagulation
antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor inhibitors: Clinical spectrum and laboratory diagnosis. Am J Hematol 45(2):
factor VIII with phospholipid. J Clin Invest 83(6):1978–1984, 1989. 128–135, 1994.
41. Nogami K, Shima M, Hosokawa K, et al: Factor VIII C2 domain contains the 70. Schoenecker JG, Johnson RK, Fields RC, et al: Relative purity of thrombin-based hemo-
thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol static agents used in surgery. J Am Coll Surg 197(4):580–590, 2003.
Chem 275(33):25774–25780, 2000. 71. Zehnder JL, Leung LL: Development of antibodies to thrombin and factor V with
42. Nogami K, Shima M, Hosokawa K, et al: Role of factor VIII C2 domain in factor VIII recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76(10):
binding to factor Xa. J Biol Chem 274(43):31000–31007, 1999. 2011–2016, 1990.
43. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of 72. Knobl P, Lechner K: Acquired factor V inhibitors. Baillieres Clin Haematol 11(2):
factor VIII in binding to von Willebrand factor. J Biol Chem 269(15):11601–11605, 1994. 305–318, 1998.
44. Meeks SL, Healey JF, Parker ET, et al: Nonclassical anti-C2 domain antibodies are pres- 73. Caers J, Reekmans A, Jochmans K, et al: Factor V inhibitor after injection of human
ent in patients with factor VIII inhibitors. Blood 112(4):1151–1153, 2008. thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 35(6):542–544, 2003.
45. Algiman M, Dietrich G, Nydegger UE, et al: Natural antibodies to factor VIII (anti- 74. Arnaud E, Lafay M, Gaussem P, et al: An autoantibody directed against human
hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A 89(9):3795–3799, thrombin anion-binding exosite in a patient with arterial thrombosis: Effects on plate-
1992. lets, endothelial cells, and protein C activation. Blood 84(6):1843–1850, 1994.
46. Gilles JG, Saint-Remy JM: Healthy subjects produce both anti-factor VIII and specific 75. La Spada AR, Skalhegg BS, Henderson R, et al: Brief report: Fatal hemorrhage in a
anti-idiotypic antibodies. J Clin Invest 94(4):1496–1505, 1994. patient with an acquired inhibitor of human thrombin. N Engl J Med 333(8):494–497,
47. Guilbert B, Dighiero G, Avrameas S: Naturally occurring antibodies against nine com- 1995.
mon antigens in human sera. I. Detection, isolation and characterization. J Immunol 76. Lian F, He L, Colwell NS, et al: Anticoagulant activities of a monoclonal antibody that
128(6):2779–2787, 1982. binds to exosite II of thrombin. Biochemistry 40(29):8508–8513, 2001.
48. Baudo F, Collins P, Huth-Kuhne A, et al: Management of bleeding in acquired hemo- 77. Sie P, Bezeaud A, Dupouy D, et al: An acquired antithrombin autoantibody directed
philia A: Results from the European Acquired Haemophilia (EACH2) Registry. Blood toward the catalytic center of the enzyme. J Clin Invest 88(1):290–296, 1991.
120(1):39–46, 2012. 78. Macedo-Ribeiro S, Bode W, Huber R, et al: Crystal structures of the membrane-binding
49. Ludlam CA, Morrison AE, Kessler C: Treatment of acquired hemophilia. Semin C2 domain of human coagulation factor V. Nature 402(6760):434–439, 1999.
Hematol 31(2 Suppl 4):16–19, 1994. 79. Ortel TL, Devore-Carter D, Quinn-Allen M, Kane WH: Deletion analysis of recom-
50. Kasper CK, Aledort L, Aronson D, et al: Proceedings: A more uniform measurement of binant human factor V. Evidence for a phosphatidylserine binding site in the second
factor VIII inhibitors. Thromb Diath Haemorrh 34(2):612, 1975. C-type domain. J Biol Chem 267(6):4189–4198, 1992.
51. Verbruggen B, Novakova I, Wessels H, et al: The Nijmegen modification of the Bethesda 80. Izumi T, Kim SW, Greist A, et al: Fine mapping of inhibitory anti-factor V antibodies
assay for factor VIII:C inhibitors: Improved specificity and reliability. Thromb Haemost using factor V C2 domain mutants. Identification of two antigenic epitopes involved in
73(2):247–251, 1995. phospholipid binding. Thromb Haemost 85(6):1048–1054, 2001.
52. Giles AR, Verbruggen B, Rivard GE, et al: A detailed comparison of the performance 81. Ortel TL, Moore KD, Quinn-Allen MA, et al: Inhibitory anti-factor V antibodies bind
of the standard versus the Nijmegen modification of the Bethesda assay in detecting to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood
factor VIII:C inhibitors in the haemophilia A population of Canada. Association of 91(11):4188–4196, 1998.
Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific 82. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Anti-phospholipid antibodies
and Standardization Committee of International Society on Thrombosis and Haemo- are directed against a complex antigen that includes a lipid-binding inhibitor of coag-
stasis. Thromb Haemost 79(4):872–875, 1998. ulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87(11):
53. Batty P, Platton S, Bowles L, et al: Pre-analytical heat treatment and a FVIII ELISA 4120–4124, 1990.
improve factor VIII antibody detection in acquired haemophilia A. Br J Haematol 83. Fleck RA, Rapaport SI, Rao LV: Anti-prothrombin antibodies and the lupus anticoagu-
166(6):953–956, 2014. lant. Blood 72(2):512–519, 1988.
54. Soucie JM, Miller CH, Kelly FM, et al: A study of prospective surveillance for inhibi- 84. Feinstein DI, Rapaport SI: Acquired inhibitors of blood coagulation. Prog Hemost
tors among persons with haemophilia in the United States. Haemophilia 20(2):230–237, Thromb 1:75–95, 1972.
2014. 85. Lakos G, Kiss E, Regeczy N, et al: Antiprothrombin and antiannexin V antibodies
55. Biggs R, Austen DE, Denson KW, et al: The mode of action of antibodies which destroy imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol
factor VIII. II. Antibodies which give complex concentration graphs. Br J Haematol 27(4):924–929, 2000.
23(2):137–155, 1972. 86. Bajaj SP, Rapaport SI, Fierer DS, et al: A mechanism for the hypoprothrombinemia
56. Hoyer LW, Scandella D: Factor VIII inhibitors: Structure and function in autoantibody of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61(4):
and hemophilia A patients. Semin Hematol 31(2 Suppl 4):1–5, 1994. 684–692, 1983.
57. Collins PW, Chalmers E, Hart DP, et al: Diagnosis and treatment of factor VIII and IX 87. Edson JR, Vogt JM, Hasegawa DK: Abnormal prothrombin crossed-immunoelectro-
inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors phoresis in patients with lupus inhibitors. Blood 64(4):807–816, 1984.
Organization. Br J Haematol 160(2):153–170, 2013. 88. Mitchell CA, Rowell JA, Hau L, et al: A fatal thrombotic disorder associated with an
58. Franchini M, Lippi G: The use of desmopressin in acquired haemophilia A: A system- acquired inhibitor of protein C. N Engl J Med 317(26):1638–1642, 1987.
atic review. Blood Transfus 9(4):377–382, 2011. 89. Sorice M, Arcieri P, Griggi T, et al: Inhibition of protein S by autoantibodies in patients
59. Astermark J, Donfield SM, DiMichele DM, et al: A randomized comparison of bypass- with acquired protein S deficiency. Thromb Haemost 75(4):555–559, 1996.
ing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Compar- 90. Nojima J, Kuratsune H, Suehisa E, et al: Acquired activated protein C resistance associ-
ative (FENOC) Study. Blood 109(2):546–551, 2007. ated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
60. Young G, Sorensen B, Dargaud Y, et al: Thrombin generation and whole blood viscoe- Thromb Haemost 88(5):716–722, 2002.
lastic assays in the management of hemophilia: Current state of art and future perspec- 91. Hurtado V, Montes R, Gris JC, et al: Autoantibodies against EPCR are found in anti-
tives. Blood 121(11):1944–1950, 2013. phospholipid syndrome and are a risk factor for fetal death. Blood 104(5):1369–1374,
61. Brettler DB, Forsberg AD, Levine PH, et al: The use of porcine factor VIII concentrate 2004.
(Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multi- 92. Boggio LN, Green D: Acquired hemophilia. Rev Clin Exp Hematol 5(4):389–404; quiz
center US experience. Arch Intern Med 149(6):1381–1385, 1989. following 431, 2001.
62. Hay CR: Porcine factor VIII: Past, present and future. Haematologica 85(10 Suppl): 93. Krishnamurthy P, Hawche C, Evans G, Winter M: A rare case of an acquired inhibitor
21–24; discussion 24–25, 2000. to factor IX. Haemophilia 17(4):712–713, 2011.
63. Kruse-Jarres R, St-Louis J, Greist A, et al: Efficacy and safety of OBI-1, an antihaemo- 94. Nawarawong W, Wyshock E, Meloni FJ, et al: The rate of fibrinopeptide B release mod-
philic factor VIII (recombinant), porcine sequence, in subjects with acquired haemo- ulates the rate of clot formation: A study with an acquired inhibitor to fibrinopeptide B
philia A. Haemophilia 21(2):162–170,2015. release. Br J Haematol 79(2):296–301, 1991.
64. Kempton CL, Abshire TC, Deveras RA, et al: Pharmacokinetics and safety of OBI-1, 95. Ruiz-Arguelles A: Spontaneous reversal of acquired autoimmune dysfibrinogenemia
a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idi-
Haemophilia 18(5):798–804, 2012. otype expressed on antifibrinogen antibodies. J Clin Invest 82(3):958–963, 1988.
65. Collins P, Baudo F, Huth-Kuhne A, et al: Consensus recommendations for the diagnosis 96. Aguilar C, Lucia JF, Hernandez P: A case of an inhibitor autoantibody to coagulation
and treatment of acquired hemophilia A. BMC Res Notes 3:161, 2010. factor VII. Haemophilia 9(1):119–120, 2003.

Kaushansky_chapter 127_p2183-2190.indd 2188 17/09/15 3:44 pm